This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n10http://localhost/temp/predkladatel/
n11http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n6http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11110%2F14%3A10288997%21RIV15-MSM-11110___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11110%2F14%3A10288997%21RIV15-MSM-11110___
rdf:type
n6:Vysledek skos:Concept
dcterms:description
The authors present an overview of the most often discussed questions concerning citalopram, i.e. its proven effect on the QT interval and related dose reductions. They discuss citalopram's antiplatelet effect including the most recent data and draw attention to serotonin syndrome as its incidence is still underestimated. They go on to discuss hyponatremia pointing out that this condition may develop even in those taking low doses of citalopram. Finally, the authors provide a brief overview of the latest findings on osteoporosis and the serotonergic mechanism inducing it in individuals treated with a selective serotonin reuptake inhibitor. The authors present an overview of the most often discussed questions concerning citalopram, i.e. its proven effect on the QT interval and related dose reductions. They discuss citalopram's antiplatelet effect including the most recent data and draw attention to serotonin syndrome as its incidence is still underestimated. They go on to discuss hyponatremia pointing out that this condition may develop even in those taking low doses of citalopram. Finally, the authors provide a brief overview of the latest findings on osteoporosis and the serotonergic mechanism inducing it in individuals treated with a selective serotonin reuptake inhibitor.
dcterms:title
The non-antidepressant effects of citalopram: a clinician's perspective The non-antidepressant effects of citalopram: a clinician's perspective
skos:prefLabel
The non-antidepressant effects of citalopram: a clinician's perspective The non-antidepressant effects of citalopram: a clinician's perspective
skos:notation
RIV/00216208:11110/14:10288997!RIV15-MSM-11110___
n3:aktivita
n12:I
n3:aktivity
I
n3:cisloPeriodika
1
n3:dodaniDat
n7:2015
n3:domaciTvurceVysledku
n11:5586178 n11:3877485
n3:druhVysledku
n14:J
n3:duvernostUdaju
n8:S
n3:entitaPredkladatele
n15:predkladatel
n3:idSjednocenehoVysledku
32717
n3:idVysledku
RIV/00216208:11110/14:10288997
n3:jazykVysledku
n16:eng
n3:klicovaSlova
osteoporosis; hyponatremia; serotonin syndrome; platelet aggregation; citalopram
n3:klicoveSlovo
n4:citalopram n4:serotonin%20syndrome n4:hyponatremia n4:platelet%20aggregation n4:osteoporosis
n3:kodStatuVydavatele
SE - Švédské království
n3:kontrolniKodProRIV
[1E0B0A7E1628]
n3:nazevZdroje
Neuroendocrinology Letters
n3:obor
n17:FE
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
3
n3:rokUplatneniVysledku
n7:2014
n3:svazekPeriodika
35
n3:tvurceVysledku
Alušík, Š. Paluch, Zoltán Richter, Tomáš
n3:wos
000340153500002
s:issn
0172-780X
s:numberOfPages
6
n10:organizacniJednotka
11110